4D Molecular Therapeutics, Inc. (FDMT) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | -179.18M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $-179.18M | (m) |
| 2026-03-31 | (m) | $-160.90M | (m) |
| 2025-12-31 | (m) | $-140.11M | (m) |
| 2025-09-30 | (m) | $-209.18M | (m) |
| 2025-06-30 | (m) | $-196.14M | (m) |
| 2025-03-31 | (m) | $-176.44M | (m) |
| 2024-12-31 | (m) | $-160.87M | (m) |
| 2024-09-30 | (m) | $-143.48M | (m) |
| 2024-06-30 | (m) | $-109.89M | (m) |
| 2024-03-31 | (m) | $-104.56M | (m) |
| 2023-12-31 | (m) | $-100.84M | (m) |
| 2023-09-30 | (m) | $-95.93M | (m) |
| 2023-06-30 | (m) | $-111.37M | (m) |
| 2023-03-31 | (m) | $-109.84M | (m) |
| 2022-12-31 | (m) | $-107.49M | (m) |
| 2022-09-30 | (m) | $-105.20M | (m) |
| 2022-06-30 | (m) | $-101.75M | (m) |
| 2022-03-31 | (m) | $-81.25M | (m) |
| 2021-12-31 | (m) | $-71.32M | (m) |
| 2021-09-30 | (m) | $-66.78M | (m) |
| 2021-06-30 | (m) | $-52.38M | (m) |
| 2021-03-31 | (m) | $-59.94M | (m) |
| 2020-12-31 | (m) | $-56.69M | (m) |
| 2020-09-30 | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) |
| 2019-12-31 | (m) | $-49.31M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |